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Sir,
Beta-atrophy in
Q1
Alzheimer's disease
Several studies have shown optic nerve changes in
Alzheimer’s disease (AD).1–3 Parapapillary atrophy is
classiﬁed into two zones:4 alpha- and beta-atrophy. Beta-
atrophy is between the disc and the rim of alpha-atrophy,
and appears as small grey ﬁelds on a whitish background.
Beta-atrophy area measurement is said by Jonas to be
more reproducible than the alpha-atrophy area, and is
suggested as a preferred outcome.4 Parapapillary atrophy
has never been measured in AD until our prospective
case–control study, the methods of which are described
elsewhere.5 The following two populations were sampled:
AD patients for cases and cognitively intact individuals
over 65 for comparators. Ethical committee approval was
granted. Dilated stereoscopic optic disc photography was
performed, and all gradings were performed by one
masked investigator (MM). A hand-held stereoscope,
touch-activated drawing pad, and ‘DiscArea’ software
(University of Iowa, Iowa city, IA, USA) were used.
Ungradable disc photographs were excluded. Each
participant's right eye was assessed unless ungradable or
unavailable; then, the left eye was used. Five per cent of
images were selected using random number tables and
regraded by an experienced grader (GS). For beta-atrophy
area, the intra-observer (kappa= 0.55) and inter-observer
agreements were 'moderate' (kappa= 0.51). The mean age
of all comparators (n= 322) was 77 years (SD 6.8 years)
and that of cases (n= 258) 80 years (SD 7.7 years). Images
were gradable in 193 cases and 274 comparators. In an
univariate analysis, area of beta-atrophy was not
associated with AD status (P= 0.4). Potentially
confounding variables were picked. There was a
signiﬁcant difference (Mann–Whitney U-test; Po0.001)
between the ages of AD cases and comparators, and age
was, therefore, included in all models. Smoking was
associated with the AD status (χ2= 4.4, df= 1, P= 0.04),
and the given reported association of smoking with
primary open angle glaucoma, smoking status was
included. A diagnosis of glaucoma had been made
and/or topical ocular hypotensive agents were being
used in 3.7% of comparators (12/322) and 6.2% of cases
(16/258; χ2= 1.9, df= 1, P= 0.17). Systemic beta-blockers
were used by 25.4% of comparators (75/295) and by
18.6% of AD cases (44/237; χ2= 3.6, df= 1, P= 0.059). Area
of beta-atrophy (in pixels) was positively skewed: after
log transformation to base 10, distribution was normal.
Binary logistic regression with AD status (case or
comparator) as the dependent variable and backward
stepwise elimination led to a model in which age
(Po0.001, OR= 1.005, 95% CIs 1.0002–1.007) and use of
systemic beta-blockers (P= 0.032, ORs= 1.7, 95% CIs
1.0–2.9) were associated with the AD status, but log10
beta-atrophy area was not (P= 0.670, ORs= 1.000). As in
any clinical study on AD, ‘cases’ may have included some
mixed or even vascular dementia cases; however, this
study has a large sample size compared with previous
studies on ophthalmic ﬁndings and AD. Analysis of
ocular changes has potential value for the early detection
of or monitoring of AD. Retinal photography does not
rely on expensive or unwieldy equipment. The ﬁndings
from our sample, however, suggest that beta-atrophy area
would not be a useful measure in an AD test-battery.
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